Form 4: Johnson & Johnson Sells CVRx Shares

Johnson & Johnson, through its subsidiary, sold 6,337 shares of CVRx, Inc. common stock for a weighted average price of $10.03 per share.

Summary

• Johnson & Johnson, through its wholly-owned subsidiary Johnson & Johnson Innovation JJDC, Inc., reported a sale of CVRx, Inc. common stock.
• The transaction involved the disposition of 6,337 shares on November 26, 2025.
• The shares were sold at a weighted average price of $10.03, with individual transactions ranging from $10.00 to $10.23 per share.
• Following this transaction, Johnson & Johnson Innovation JJDC, Inc. indirectly beneficially owns 4,040,861 shares of CVRx, Inc. common stock.
• The sale was conducted pursuant to a Rule 10b5-1(c) plan, indicating a pre-arranged transaction.

Sentiment

Score: 5

Explanation: The filing reports a routine insider stock sale by a 10% owner under a pre-arranged 10b5-1 plan, which is a standard disclosure and does not inherently indicate a strong positive or negative sentiment regarding the company's performance.

Negatives

• Johnson & Johnson, a 10% owner and director, reduced its beneficial ownership in CVRx, Inc. by selling 6,337 shares.

Industry Context

This filing represents a routine insider transaction where a large institutional investor, Johnson & Johnson, through its corporate venture arm JJDC, manages its portfolio stake in CVRx, Inc. Such sales, especially when conducted under a Rule 10b5-1 plan, are common practice for institutional investors to rebalance portfolios or meet pre-determined liquidity needs.

Related Party Transactions

• Johnson & Johnson, a 10% owner and director of CVRx, Inc., through its wholly-owned subsidiary Johnson & Johnson Innovation JJDC, Inc., sold shares of CVRx, Inc. common stock.

Stakeholder Impact

• Shareholders: The reduction in beneficial ownership by a significant institutional investor, Johnson & Johnson, could be viewed as a neutral event given it was executed under a pre-arranged 10b5-1 plan, but it does represent a slight decrease in institutional conviction.

Key Dates

Recommendation

The filing details a routine, pre-scheduled sale of a small portion of CVRx, Inc. shares by Johnson & Johnson, a 10% owner, under a Rule 10b5-1 plan. This type of transaction is generally considered a portfolio management activity rather than a signal of fundamental change in the company's prospects, thus warranting a 'hold' recommendation based solely on this disclosure.

Keywords

CVRx, Johnson & Johnson, JJDC, stock sale, insider transaction, Form 4, beneficial ownership, 10b5-1 plan